Key terms

About RVNC

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest RVNC news

Mar 04 9:33am ET Revance 16M share Spot Secondary priced at $6.25 Mar 04 6:41am ET Revance announces $100M offering of common stock Mar 01 8:15am ET Revance price target raised to $16 from $15 at Guggenheim Feb 29 5:19pm ET Revance price target raised to $9 from $8 at Goldman Sachs Feb 29 11:01am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (RVNC), VYNE Therapeutics (VYNE) and Ironwood Pharma (IRWD) Feb 29 8:17am ET Revance Therapeutics (RVNC) Gets a Buy from Stifel Nicolaus Feb 29 7:48am ET Revance Therapeutics (RVNC) Receives a Buy from Piper Sandler Feb 29 7:43am ET Revance price target lowered to $20 from $42 at Piper Sandler Feb 29 7:11am ET Analysts Are Bullish on These Healthcare Stocks: Avidity Biosciences (RNA), Revance Therapeutics (RVNC) Feb 29 6:40am ET Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC) Feb 29 2:45am ET Revance Therapeutics (RVNC) Gets a Buy from Barclays Feb 28 6:45pm ET Revance Therapeutics: Strategic Pivot and Growth Potential Justify Buy Rating Feb 28 4:23pm ET Revance Therapeutics Renews Manufacturing Deal and Announces Executive Transition Feb 28 4:15pm ET Revance sees FY24 product revenue at least $280M Feb 28 4:15pm ET Revance reports Q4 EPS (62c), consensus (72c) Feb 23 7:45am ET Revance price target lowered to $12 from $15 at H.C. Wainwright Feb 23 3:05am ET Barclays Remains a Buy on Revance Therapeutics (RVNC) Feb 13 4:46pm ET Revance Therapeutics Sets 2024 Goals, Updates Executive Severance Plan Feb 07 4:45am ET Revance Therapeutics Sets Executive Compensation for 2024 Feb 02 8:09am ET Revance announces CMS assigns permanent J-code for Daxxify Jan 29 5:07am ET Barclays Keeps Their Buy Rating on Revance Therapeutics (RVNC) Jan 12 7:40am ET Revance price target lowered to $30 from $35 at Stifel Jan 12 7:37am ET Stifel Nicolaus Sticks to Their Buy Rating for Revance Therapeutics (RVNC) Jan 11 1:57am ET Revance Therapeutics: A Strong Buy on Undervalued Stock and Growth Prospects Jan 09 10:25am ET Maintained Buy Rating on Revance Therapeutics Amidst Conservative Sales Guidance and Long-Term Growth Potential Jan 09 8:40am ET Analysts Are Neutral on Top Healthcare Stocks: Revance Therapeutics (RVNC), Roche Holding AG (RHHVF) Jan 09 8:25am ET Revance downgraded to Neutral from Buy at Goldman Sachs Jan 09 6:17am ET Buy Rating on Revance Therapeutics: Balancing Near-Term Challenges with Long-Term RHA Filler Potential Jan 08 11:25am ET Strong Buy Rating for Revance Therapeutics Amidst Promising Drug Prospects and Solid Financials

No recent news articles are available for RVNC

No recent press releases are available for RVNC

RVNC Financials

1-year income & revenue

Key terms

RVNC Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

RVNC Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms